z-logo
Premium
Consensus statement on the loco‐regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)
Author(s) -
Moran Brendan,
Baratti Dario,
Yan Tristan D.,
Kusamura Shigeki,
Deraco Marcello
Publication year - 2008
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21054
Subject(s) - pseudomyxoma peritonei , medicine , appendix , general surgery , mucinous tumor , surgery , paleontology , biology , pancreas
Pseudomyxoma peritonei (PMP) is a rare condition mostly originating from low malignant potential mucinous tumours of the appendix. Although this disease process is minimally invasive and rarely causes haematogenous or lymphatic metastases, expectation of long‐term survival are limited with no prospect of cure. Recently, the combined approach of cytoreductive surgery (CRS) and perioperative loco‐regional chemotherapy (PLC) has been proposed as the standard of treatment for the disease. The present paper summarizes the available literature data and the main features of the comprehensive loco‐regional treatment of PMP. The controversial issues concerning the indications and technical methodology in PMP management were discussed through a web‐based voting system by internationally known experts. Results were presented for further evaluation during a dedicated session of “The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006)”. The experts agreed that multiple prospective trials support a benefit of the procedure in terms of improved survival, as compared with historical controls. Concerning the main controversial methodological questions, there was an high grade of consistency among the experts and agreement with the findings of the literature. J. Surg. Oncol. 2008;98:277–282. © 2008 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here